MG
MGTX.US MeiraGTx Holdings PLC
- Market cap
- USD 854M
- P/E
- 10.0x
- P/B
- 4.18x
- ROE
- 39.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MGTX.US undervalued?
Graham numberMGTX.US trades 36.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MeiraGTx Holdings PLC fundamental analysis
No fundamental analysis for MeiraGTx Holdings PLC yet.
MeiraGTx Holdings PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MeiraGTx Holdings PLC
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkin…
Full company profileMeiraGTx Holdings PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MeiraGTx Holdings PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 13.3M | 15.6M | 37.7M | 15.9M | 14.0M | 33.3M | 81.4M | 435M |
| Gross Profit | -243K | -679K | -2.05M | 13.3M | 15.6M | 37.7M | 15.9M | 14.0M | 9.49M | 76.5M | 413M |
| Operating Income | -20.1M | -31.7M | -78.1M | -58.3M | -62.6M | -72.8M | -116M | -137M | -164M | -106M | 205M |
| EBITDA | -19.8M | -31.0M | -76.1M | -52.5M | -53.7M | -71.4M | -116M | -57.1M | -122M | -89.5M | 317M |
| Net Income | -19.5M | -31.0M | -82.9M | -54.7M | -58.0M | -79.6M | -130M | -84.0M | -148M | -114M | 84.3M |
| EPS | -1.01 | -3.62 | -4.37 | -1.65 | -1.54 | -1.80 | -2.87 | -1.49 | -2.12 | -1.42 | 0.87 |
| Balance Sheet | |||||||||||
| Total Assets | 22.6M | 25.9M | 96.9M | 324M | 364M | 320M | 318M | 327M | 270M | 244M | 412M |
| Total Liabilities | 39.7M | 73.2M | 15.8M | 133M | 125M | 135M | 200M | 189M | 202M | 250M | 196M |
| Shareholders' Equity | -17.1M | -47.4M | 81.1M | 191M | 239M | 185M | 118M | 138M | 67.8M | -5.79M | 215M |
| Cash & Short-term Investments | 17.5M | 8.55M | 68.1M | 227M | 210M | 138M | 116M | 130M | 104M | 65.9M | 185M |
| Total Debt | 11.5K | 1.51M | 34.3K | 23.2M | 22.2M | 23.7M | 92.2M | 89.3M | 84.8M | 88.7M | 134M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.4M | -18.1M | -58.9M | 20.0M | -64.0M | -10.5M | -73.1M | -105M | -104M | -46.4M | -60.4M |
| Capital Expenditure | 2.59M | 10.5M | 11.3M | 8.98M | 37.0M | 55.2M | 45.0M | 20.2M | 4.96M | 3.83M | 5.43M |
| Free Cash Flow | -17.0M | -28.6M | -70.1M | 11.1M | -101M | -65.7M | -118M | -126M | -109M | -50.2M | -65.8M |
| Ratios | |||||||||||
| ROE | - | - | -102.2% | -28.7% | -24.3% | -42.9% | -110.1% | -60.8% | -217.9% | - | 39.2% |
| ROA | -86.4% | -120.1% | -85.5% | -16.9% | -15.9% | -24.9% | -40.7% | -25.7% | -54.8% | -46.7% | 20.5% |
| Net Profit Margin | - | - | - | -411.9% | -372.6% | -211.0% | -814.2% | -599.5% | -444.1% | -140.3% | 19.4% |
| Debt to Equity | - | - | 0.00x | 0.12x | 0.09x | 0.13x | 0.78x | 0.65x | 1.25x | - | 0.62x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MeiraGTx Holdings PLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 70.0M | 1.55 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns MeiraGTx Holdings PLC
- Insiders 16.03%
- Institutions 73.23%
- Public & others 10.74%
- Shares outstanding 97.7M
- Free float 55.5M
Top funds holding MGTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.50M | 1.54% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 658K | 0.67% | 0.00% | Aug 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 625K | 0.64% | +0.43% | Oct 2026 |
| iShares Biotechnology ETF | 568K | 0.58% | -0.19% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 535K | 0.55% | +1.63% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 441K | 0.45% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 349K | 0.36% | +0.96% | Sep 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 260K | 0.27% | +0.08% | Oct 2026 |
| Canada Life US Small-Mid Cap Growth F | 255K | 0.26% | 0.00% | Aug 2026 |
| Janus Henderson Small Cap Gr Alpha ETF | 234K | 0.24% | 0.00% | Oct 2026 |
| CREF Total Global Stock Account R3 | 231K | 0.24% | +72.21% | Sep 2026 |
| First Trust Small Cap Core AlphaDEX® ETF | 230K | 0.24% | 0.00% | Oct 2026 |
| Assenagon Funds Value Size Global RS | 225K | 0.23% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 183K | 0.19% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 169K | 0.17% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 145K | 0.15% | -0.11% | Sep 2026 |
| ALPS Medical Breakthroughs ETF | 118K | 0.12% | 0.00% | Oct 2026 |
| iShares Russell 2000 Value ETF | 116K | 0.12% | 0.00% | Oct 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 115K | 0.12% | -0.54% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 113K | 0.12% | 0.00% | Sep 2026 |
Top institutions holding MGTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sanofi | 12.2M | 12.50% | 0.00% | Sep 2026 |
| Perceptive Advisors LLC | 10.8M | 11.05% | +4.46% | Jun 2026 |
| Rubric Capital Management LP | 9.10M | 9.32% | +30.00% | Jun 2026 |
| Johnson & Johnson | 6.64M | 6.80% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.76M | 4.87% | +50.16% | Jun 2026 |
| Adage Capital Partners Gp LLC | 4.40M | 4.51% | +10.00% | Jun 2026 |
| Opaleye Management Inc | 3.55M | 3.64% | +67.20% | Jun 2026 |
| Millennium Management LLC | 2.97M | 3.04% | -14.25% | Jun 2026 |
| Woodline Partners LP | 1.50M | 1.54% | +399.51% | Jun 2026 |
| State Street Corp | 1.39M | 1.43% | +84.93% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.31M | 1.34% | -17.44% | Jun 2026 |
| Knoll Capital Management LP | 1.25M | 1.28% | 0.00% | Jun 2026 |
| Kennedy Capital Management Inc | 1.11M | 1.13% | +28.78% | Jun 2026 |
| Long Focus Capital Management, LLC | 1.08M | 1.11% | +105.87% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.02M | 1.04% | +7,324.16% | Jun 2026 |
| D. E. Shaw & Co LP | 853K | 0.87% | +100.55% | Jun 2026 |
| Heights Capital Management Inc | 850K | 0.87% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 849K | 0.87% | +45.17% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 724K | 0.74% | +82.13% | Jun 2026 |
| Erste Asset Management GmbH | 691K | 0.71% | -3.96% | Jun 2026 |
MeiraGTx Holdings PLC company profile
- Company name
- MeiraGTx Holdings PLC
- Ticker
- MGTX.US
- ISIN
- KYG596651029
- Exchange
- USA Stocks
- Listed since
- Jun 8, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 386
- Fiscal year end
- December
- Address
- 655 Third Avenue, New York, NY, United States, 10017
- Phone
- 646 860 7985
- Website
- meiragtx.com
About MeiraGTx Holdings PLC
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
MeiraGTx Holdings PLC management
10- Dr. Alexandria Forbes Ph.D.CEO, President & Director · born 1965
- Mr. Richard Brian Giroux B.A.COO & CFO · born 1974
- Dr. Robert K. Zeldin M.D.Chief Medical Officer · born 1963
- Mr. Robert J. Wollin J.D.General Counsel & Secretary · born 1976
- Dr. Stuart Naylor Ph.D.Chief Scientific Officer of Ophthalmology · born 1963
- Dr. Michel Michaelides F.A.C.S., M.D., MBBSHead of Clinical Ophthalmology
- Ms. Christine Elise SheehySenior Vice President of Global Integration · born 1968
- Mr. Tim RandallSenior Vice President of Risk & Internal Controls
- Dr. David Rubinstein Ph.D.Senior Vice President of Business Development
- Dr. Tassos Georgiadis Ph.D.Senior Vice President of Discovery & Preclinical Development